These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 32652869)

  • 1. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
    Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
    Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma.
    Sharma R; Kadife E; Myers M; Kannourakis G; Prithviraj P; Ahmed N
    J Exp Clin Cancer Res; 2021 Jun; 40(1):186. PubMed ID: 34099013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
    Gill DM; Hahn AW; Hale P; Maughan BL
    Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current State of Systemic Therapies for Advanced Renal Cell Carcinoma.
    Gulati S; Vaishampayan U
    Curr Oncol Rep; 2020 Feb; 22(3):26. PubMed ID: 32048058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
    Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
    Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
    Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
    Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma.
    Chehrazi-Raffle A; Meza L; Alcantara M; Dizman N; Bergerot P; Salgia N; Hsu J; Ruel N; Salgia S; Malhotra J; Karczewska E; Kortylewski M; Pal S
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
    Tang PA; Vickers MM; Heng DY
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):871-91. PubMed ID: 21763972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.
    Graham J; Wells JC; Dudani S; Gan CL; Donskov F; Lee JL; Kollmannsberger CK; Meza L; Beuselinck B; Hansen A; North SA; Bjarnason GA; Sayegh N; Kanesvaran R; Wood LA; Hotte SJ; McKay RR; Choueiri TK; Heng DYC
    Eur J Cancer; 2022 Aug; 171():124-132. PubMed ID: 35717820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.
    Ciccarese C; Iacovelli R; Brunelli M; Massari F; Bimbatti D; Fantinel E; De Marco V; Porcaro AB; Martignoni G; Artibani W; Tortora G
    Eur J Cancer; 2017 Sep; 83():237-246. PubMed ID: 28756136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma.
    Sekino Y; Teishima J; Liang G; Hinata N
    Int J Urol; 2022 Dec; 29(12):1419-1428. PubMed ID: 36122306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms.
    Buczek M; Escudier B; Bartnik E; Szczylik C; Czarnecka A
    Biochim Biophys Acta; 2014 Jan; 1845(1):31-41. PubMed ID: 24135488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Tyrosine Kinase Inhibitor
    Miyake H; Imai S; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
    Anticancer Res; 2017 Mar; 37(3):1523-1528. PubMed ID: 28314328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy.
    Park JY; Lee JL; Baek S; Eo SH; Go H; Ro JY; Cho YM
    Hum Pathol; 2014 Jul; 45(7):1437-44. PubMed ID: 24784922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy.
    Hamieh L; Beck RL; Le VH; Hsieh JJ
    Clin Genitourin Cancer; 2020 Aug; 18(4):252-257.e2. PubMed ID: 32291161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein kinase inhibitors in renal cell carcinoma.
    Daste A; Grellety T; Gross-Goupil M; Ravaud A
    Expert Opin Pharmacother; 2014 Feb; 15(3):337-51. PubMed ID: 24328606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy.
    Ishihara H; Takagi T; Kondo T; Tachibana H; Yoshida K; Omae K; Iizuka J; Kobayashi H; Tanabe K
    Int J Clin Oncol; 2018 Jun; 23(3):559-567. PubMed ID: 29327159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition.
    Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
    Scand J Immunol; 2023 Oct; 98(4):e13304. PubMed ID: 37294700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age.
    Huang JJ; Hsieh JJ
    Semin Nephrol; 2020 Jan; 40(1):28-41. PubMed ID: 32130964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.